




CELL -BASED THERAPIES IN ONCOLOGY


2nd VHIO-BBVA Foundation International Symposium

13-14 November, 2025



UAB Casa Convalescència | Carrer de Sant Antoni Maria Claret, 171, Barcelona

Program Day 1		
8:15-9:00	Registration	
9:00-9:10	Opening remarks	Alena Gros , VHIO
Session I: Advances in Gene and Cell Therapies		Chairs: Alena Gros and Martí Farrera-Sal
9:15-10:00	Keynote lecture. Towards in vivo CAR-T	Saar Gill , University of Pennsylvania
10:00-10:25	Precision TIL Therapy for Poorly Immunogenic Metastatic Cancers	Udai Kammula , University of Pittsburgh
10:25-10:50	Academic Model for CAR-T Development: Results in Multiple Myeloma with ARI0002h and Beyond	Carlos Fernández de Larrea , IDIBAPS - Hospital Clínic Barcelona
10:50-11:15	Gene Therapy for Rare Liver Disorders: From the Bench to the Patients	Gloria González Aseguinolaza , Clínica Universidad de Navarra
11:15-11:45	Coffee break	
11:45-12:10	Novel Targets for Immune Redirection	Joaquin Arribas , VHIO/ HMRIB
12:10-12:35	A Portfolio of Cellular Immunotherapies for ALK-Driven Cancers	Roberto Chiarle , Harvard Medical School / University of Turin
12:35-13:15	Short talks session	
Development Of New Cellular Immunotherapies Against Cancer Based on T Lymphocytes Trained with Bacteria		Daniel Gomez , CNB-CSIC
Identification of Clinically Relevant T Cell Receptors for Personalized T Cell Therapy Using Combinatorial Algorithms		Rémy Pétremand , UNIL
Preclinical Characterization of ARI-007: CD7-Negative T-Cells Engineered with an Academic Anti-CD7 CAR for T-Cell Cancer Treatment		Marta Soria Castellano , IDIBAPS
13:15-14:15	Group picture and Lunch break	
14:15-14:30	Guest Lecture. Enhancing Patient Engagement in Cancer Research: A Focus on Patient-Centric Approaches to Scientific Discovery	Marta Puyol , Asociación Española Contra el Cancer (AECC)
Session II: Towards Clinical Translation		Chair: Elena Garralda
14:30-14:55	Harnessing Peripheral Blood to Create Next-Generation T Cell Therapies for Solid Cancers	Alena Gros , VHIO
14:55-15:20	Novel Inventions to Improve T cell Therapy	Sine Reker , Technical University of Denmark
15:20-15:45	tbc	Annette Kunkele , Charité – Universitätsmedizin Berlin
15:45-16:10	Short talks session	
Enhancing Anti-BCMA CAR- T Cell Therapy Response in Multiple Myeloma by Combining in Silico Perturbation Predictions and Drug Repurposing		Alessia Buratin , IJC
Embedding GMP Principles in the Development of Next-Generation Tumor-Resilient TCR-T Cells		Daniel Lycke Kristiansen , Oslo University Hospital
16:20-18:00	Poster session & Networking cocktail	
<i>*Speakers' Dinner (by invitation only) El Nacional – Pg. de Gràcia, 24 Bis . 19:30–20:30 Welcome cocktail at La Cocteleria, 20:30 Dinner at El Magatzem</i>		



CELL -BASED THERAPIES IN ONCOLOGY

2nd VHIO-BBVA Foundation International Symposium

13-14 November, 2025



UAB Casa Convalescència | Carrer de Sant Antoni Maria Claret, 171, Barcelona

Program Day 2		
Session III: Emerging Concepts in Adoptive Cell Therapy		Chair: Pere Barba
9:00-9:25	Modulating Signaling Activities to Enhance CAR-T Cell Potency	Judith Feucht , University of Tübingen
9:25-9:50	Multi-Modal Preclinical Tools to Advance CAR-T Cell Therapy in Solid Tumors	Martí Farrera-Sal , VHIO
9:50-10:15	Deconstructing aging with senolytic CAR T cells	Corina Amor , Cold Spring Harbor Laboratory
10:15-10:40	STAb-Therapy: Physiological, Multi-Target, and Multi-Effector Immune Redirection for Cancer	Luis Álvarez-Vallina , Hospital Del Mar Research Institute
10:40-11:15	Coffee break	
11:15-12:00	Short talks session	
	BACH2 Dosing Promotes Stemness Without Compromising Effector Functions to Enhance T Cell Persistence and Anti-Tumor Efficacy	Alberto Conti , University of Cambridge
	In Vivo- Based CRISPR Screen Identifies ZC3H12C as a Mediator of CAR-T Cell Dysfunction in Solid Tumors	Paula Barbao , IDIBAPS
	Unravelling Tumor-Intrinsic Resistance Mechanisms to T Cell Mediated Cytotoxicity in Pancreatic Cancer	Judit Diaz , VHIO
12:00-12:55	Roundtable discussion: Establishing Operational Networks for CGT Products in the EU	
	Chair: Silvia Martín Lluesma , VHIO	
	Manel Juan , IDIBAPS - Hospital Clínic Barcelona	
	Cristina Castilla-Llorente , Gustave Roussy	
Participants	Miquel Salas , Biocat	
	Francisco Martin , SETGYC/ GENYO	
	Johan van Eldere , European University Hospital Alliance	
13:00-14:00	Lunch break	
Session IV: Determinants of Cell Therapy Activity		Chair: Joaquin Arribas
14:00-14:25	Understanding and Exploiting Cytokine and Cellular Activity in the Extracellular Tumor Environment	Suman Mitra , University of Lille
14:25-14:50	Engineering Resilient CAR-T Cells: Strategies to Overcome Resistance	Sonia Guedan , IDIBAPS - Hospital Clínic Barcelona
14:50-15:15	Distinct TCR-Driven Transcriptional Programs Determine the Antitumor Activity of Neoantigen-Specific T Cells	Cristina Puig Saus , University of California, Los Angeles
15:15-16:00	Keynote Lecture. The Immunogenicity of Cancer Neoantigens.	Thomas Blankenstein , MDC Berlin
16:00	Closing remarks	Silvia Martín Lluesma , VHIO

Organized by:



Sponsored by:



Supported by:

